DEFENCE THERAPEUTICS APPOINTS DR.
RIAM SHAMMAA TO ITS BOARD OF DIRECTORS
Vancouver, BC,
Canada, November 9th,
2021 --
InvestorsHub NewsWire -- Defence Therapeutics
Inc. CSE:DTC, USOTC:DTCFF ("Defence"
or the "Company"),
a biotechnology company working on the development of next
generation cancer therapeutics and infectious disease vaccines is
pleased to announce the appointment of Dr. Riam Shammaa to its
board of directors, effective immediately.
Dr. Riam Shammaa, MD,
is a pioneer scientist in the fields of cell therapy and biologics
and holds several patents in the field. He conducted the first
successful spinal discs repair using stem cells in Canada. Dr.
Shammaa founded several companies in the biotechnology field
including Pallianera Pharma and Intellistem Technologies. Dr.
Shammaa has led the development of multiple successful therapeutics
to the market. Dr. Shammaa is managing director of Regen Capital,
with an investment portfolio in biotech, healthcare, fintech and
Ag-tech.
Dr. Shammaa worked in
research at McGill University and in the private sector before
completing his residency in family medicine at McGill University.
He went on to complete a fellowship in Sports medicine at the
University of Toronto. He is a published author and a
world-renowned expert in cell therapy and translational
medicine.
"We are pleased
to welcome Dr. Shammaa to joining our board of directors as a
strong and proactive member. He will certainly be an excellent
addition to our team due to his extensive knowledge in the fields
of cell therapy and biologics. Dr. Shammaa also benefits from a
large network in the US and has delt with several large pharma and
venture capital entities which will help elevate Defence's presence
and development in the US, including potential business and
partnerships" mentioned Sebastien Plouffe, Chief Executive Officer
of Defence Therapeutics.
In connection with Dr.
Shammaa appointment to the board of directors, Defence has granted
to him incentive stock options to purchase 50,000 common shares of
Defence pursuant to and in accordance with the terms and conditions
of Defence's stock option plan, subject of any regulatory approval.
Each stock option vest immediately and is exercisable at a price of
$6.50 per share for a period of three years from the granted
date.
About
Defence:
Defence
Therapeutics is a publicly-traded biotechnology company working on
engineering the next generation vaccines and ADC products using its
proprietary platform. The
core of Defence Therapeutics platform is the ACCUMTM
technology,
which enables precision delivery of vaccine antigens or ADCs in
their intact form to target cells. As a result, increased efficacy
and potency can be reached against catastrophic illness such as
cancer and infectious diseases.
For further
information:
Sebastien Plouffe,
President, CEO and Director
P: (514)
947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary
Statement Regarding "Forward-Looking" Information
This release includes
certain statements that may be deemed "forward-looking statements".
All statements in this release, other than statements of historical
facts, that address events or developments that the Company expects
to occur, are forward-looking statements. Forward-looking
statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects",
"plans", "anticipates", "believes", "intends", "estimates",
"projects", "potential" and similar expressions, or that events or
conditions "will", "would", "may", "could" or "should" occur.
Although the Company believes the expectations expressed in such
forward-looking statements are based on reasonable assumptions,
such statements are not guarantees of future performance and actual
results may differ materially from those in the forward-looking
statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include
regulatory actions, market prices, and continued availability of
capital and financing, and general economic, market or business
conditions. Investors are cautioned that any such statements are
not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on
the beliefs, estimates and opinions of the Company's management on
the date the statements are made. Except as required by applicable
securities laws, the Company undertakes no obligation to update
these forward-looking statements in the event that management's
beliefs, estimates or opinions, or other factors, should
change.
Neither the
CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or
accuracy of this release.